HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme

Molecular Neurobiology
Michel HerranzR López-López

Abstract

Glioblastoma multiforme (GBM) is the most common brain tumor in adults. The role of high in normal-1 (HIN-1) as a potential biomarker in combating this disease is being described for the first time in this study. A combination of O6-methylguanine DNA methyltransferase (MGMT) and HIN-1 methylation could be a possible biomarker in therapy choice. Interestingly, survival data shows a similar trend for the methylation of MGMT and for unmethylation of HIN-1 and vice versa. Eighty-eight paraffin-embedded brain tumors were analyzed to screen methylation rates of different genes and evaluate the association between genes methylation and clinicopathologic variables. Our study is the first of its kind to indicate that MGMT and HIN-1 methylation status are inverted (97.7% of methylated ones) and could be new markers in the study of GBM prognosis, especially in the therapy selection.

References

Sep 3, 1996·Proceedings of the National Academy of Sciences of the United States of America·J G HermanS B Baylin
Mar 30, 1999·Experimental Cell Research·R L Jirtle
Aug 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·I E KropK Polyak
Dec 17, 2002·Molecular and Cellular Biology·Yutaka KondoJean-Pierre J Issa
Nov 25, 2003·The New England Journal of Medicine·James G Herman, Stephen B Baylin
Feb 24, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antonio MarchettiFiamma Buttitta
Oct 9, 2004·International Journal of Cancer. Journal International Du Cancer·Hisayuki ShigematsuAdi F Gazdar
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Partha M Das, Rakesh Singal
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ulrich LehmannPeer Flemming
Nov 4, 2005·Cancer Research·Ian KropKornelia Polyak
Jun 5, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Qiwei YangSusan L Cohn
Dec 23, 2008·Epigenetics : Official Journal of the DNA Methylation Society·Mingzhou GuoHetty E Carraway
Nov 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickMichael Weller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.